Post Ocular Surgery
OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, designed to be the first once-daily, preservative-free steroid for treating inflammation and pain following ocular surgery
Cataract surgeries are the most prevalent procedures of all medical specialties1
Most cataracts are related to aging and by age 80, more than half of all Americans either have a cataract or have had cataract surgery.
A cataract is a clouding of the lens in the eye that affects vision. The purpose of the lens is to bend (refract) light rays that come into the eye to help people see. A natural lens is clear, but as people age, it becomes cloudy. Having a cataract can be like looking through a foggy or dusty car windshield. Things may look blurry, hazy and less colorful.
During cataract surgery, the cloudy natural lens is removed and replaced with a clear artificial lens. That lens is called an intraocular lens (IOL).
cataract surgeries are performed every year globally (~60,000 every day)1. Post ocular surgery treatment regimen requires multiple daily doses of different eye drops to alleviate inflammation and pain, as well as prevent infections.
Ophthalmic surgeries are on the rise, mainly due to the aging population and lifestyle changes. They are expected to reach close to ~10 million procedures per year in the U.S. alone by 20372.
Patients need to take multiple daily doses of eye drops to alleviate inflammation and pain
Ophthalmologists currently rely on topical steroids to treat ocular inflammation following ocular surgery as part of a regimen that includes steroids, antibiotics and NSAIDs, which can have different dosing regimens and require several drops daily, all leading to potential compliance issues. Oculis is developing OCS-01, potentially the first once-daily, high concentration, preservative-free steroid eye drop for treating inflammation and pain following ocular surgery to help address some of the remaining unmet medical needs.
OCS-01
Leveraging Oculis’ proprietary OPTIREACH® technology, OCS-01 is a once-daily high concentration eye drop candidate.
The OPTIREACH® solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling less frequent administration for front-of-the-eye and the drug passage from the eye surface to the posterior segment for back-of-the-eye diseases.
In the Phase 3 OPTIMIZE-1 clinical trial, OCS-01 eye drops met both primary endpoints with a once-daily dosing regimen for the treatment of inflammation and pain following cataract surgery.
Furthermore, OCS-01 was well tolerated with a favorable safety profile. The data is consistent with the Phase 2 SKYGGN trial for the same indication.
If approved, OCS-01 will be the first once-daily, high concentration, preservative-free steroid eye drop for treating inflammation and pain following ocular surgery.
OCS-01 eye drop is also being investigated in Phase 3 trials for diabetic macular edema (DME) and in an investigator initiated trial (IIT) for cystoid macular edema (CME).
OCS-01 is an investigational drug and has not received regulatory approval for commercial use in any country.
The OPTIREACH® solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling less frequent administration for front-of-the-eye and the drug passage from the eye surface to the posterior segment for back-of-the-eye diseases.
In the Phase 3 OPTIMIZE-1 clinical trial, OCS-01 eye drops met both primary endpoints with a once-daily dosing regimen for the treatment of inflammation and pain following cataract surgery.
Furthermore, OCS-01 was well tolerated with a favorable safety profile. The data is consistent with the Phase 2 SKYGGN trial for the same indication.
If approved, OCS-01 will be the first once-daily, high concentration, preservative-free steroid eye drop for treating inflammation and pain following ocular surgery.
OCS-01 eye drop is also being investigated in Phase 3 trials for diabetic macular edema (DME) and in an investigator initiated trial (IIT) for cystoid macular edema (CME).
OCS-01 is an investigational drug and has not received regulatory approval for commercial use in any country.
Explore OCS-01 Clinical Trials in Post Ocular Surgery
Phase 3: Results of OCS-01 Eye Drops for the Treatment of Inflammation and Pain following Cataract Surgery (OPTIMIZE-1)
Phase 2: OCS-01 in Treating Inflammation and Pain in Post-Cataract Patients (SKYGGN)
Discover Our Ophthalmic Treatment Candidates
Rethinking Ophthalmology to Save Sight and Improve Eye Care
Once daily OCS-01 could become an attractive option to treat pain and inflammation after ocular surgery with a highly potent anti-inflammatory effect. This could be especially beneficial for high-risk patients, such as diabetic patients, who face an increased risk of complications following ocular surgery due to pre-existing underlying inflammation.”